Study Reveals Public Opinion on Polygenic Embryo Screening for IVF
By Stephanie Dutchen,
Harvard Medical School
| 05. 14. 2024
At a glance:
Survey reveals nearly three-quarters of U.S. adults support using emerging technology to screen embryos during IVF for likelihood of developing certain health conditions or traits that arise from more than one gene.
Only about one-third of respondents approved of using the technology to predict traits unrelated to disease.
Nearly all expressed concerns about potential negative outcomes for individuals or society.
Findings underscore need for public education about benefits, limitations, ethical hazards of polygenic risk scores for embryos.
Three out of four adults in the U.S. support the use of emerging technologies that estimate a future child’s likelihood of developing certain health conditions influenced by multiple genes — such as diabetes, heart disease, and depression — before an embryo is implanted during in vitro fertilization (IVF), according to a new public opinion survey led by researchers at Harvard Medical School.
Results of the survey, published May 14 in JAMA Network Open, underscore the need for public education and conversation about the potential positive and negative implications of these ethically fraught technologies, the researchers said.
Although the approach...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Ewen Callaway, Nature | 08.04.2025
For months, researchers in a laboratory in Dallas, Texas, worked in secrecy, culturing grey-wolf blood cells and altering the DNA within. The scientists then plucked nuclei from these gene-edited cells and injected them into egg cells from a domestic dog ...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...